ey0021.8-15 | New Hope | ESPEYB21
A Fischer
, S Kloos
, U Maccio
, J Friemel
, H Remde
, M Fassnacht
, C Pamporaki
, G Eisenhofer
, HJLM Timmers
, M Robledo
, SMJ Fliedner
, K Wang
, J Maurer
, A Reul
, K Zitzmann
, N Bechmann
, G Žygienė
, S Richter
, C Hantel
, D Vetter
, K Lehmann
, H Mohr
, NS Pellegata
, M Ullrich
, J Pietzsch
, CG Ziegler
, SR Bornstein
, M Kroiss
, M Reincke
, K Pacak
, AB Grossman
, F Beuschlein
, S Nolting
Brief Summary: This study explored the relationship between Somatostatin Receptor 2 (SSTR2) immunoreactivity and succinate dehydrogenase complex iron sulfur subunit B (SDHB) immunoreactivity, mutational status, and clinical behavior of paragangliomas (PPGLs), and evaluated SSTR-based therapies in metastatic PPGLs. The findings highlight SSTR2 expression as a novel biomarker for metastatic behavior in PCC, PGL and SDHB/ SDHx mutations. They also suggest that SSTR-based therapie...